It has been described that gene therapy using exogenous frataxin can reverse FDRA symptoms in an FXN knock-out mouse model, increasing life expectancy and Fe-S bioavailability, which indicates that its pathophysiology is directly related to frataxin deficiency [55, 56]. This evidence concerns the gene FXN and hyperinsulinemic hypoglycemia, familial, 4.